D. E. Shaw & Co., Inc. Immatics N.V. Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Immatics N.V. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 29,463 shares of IMTX stock, worth $165,287. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,463
Previous 24,734
19.12%
Holding current value
$165,287
Previous $175,000
24.57%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding IMTX
# of Institutions
82Shares Held
91.5MCall Options Held
201KPut Options Held
109K-
T. Rowe Price Investment Management, Inc. Baltimore, MD14.7MShares$82.3 Million0.04% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$52.6 Million1.77% of portfolio
-
Suvretta Capital Management, LLC New York, NY9.14MShares$51.2 Million1.8% of portfolio
-
Wellington Management Group LLP Boston, MA8.58MShares$48.2 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY7.28MShares$40.8 Million0.39% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $428M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...